Enterprise Value
294.6M
Cash
119.2M
Avg Qtr Burn
-26.18M
Short % of Float
6.10%
Insider Ownership
17.36%
Institutional Own.
61.20%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bota-vec (Botaretigene sparoparvovec) (AAV-RPGR) Details X-linked retinitis pigmentosa, Genetic disorder, Eye disease | Phase 3 Update | |
AAV-RPE65 Details Eye disease , Retinal dystrophy | Phase 3 Initiation | |
AAV-CNGB3 Details Achromatopsia, Genetic disorder, Autosomal recessive congenital ichthyosis , Skin disease/disorder | Phase 2b Update | |
AAV-CNGA3 Details Achromatopsia | Phase 2b Update | |
AAV-hAQP1 Details Salivary gland | Phase 2 Data readout | |
AAV-GAD Details Parkinson's disease | Phase 2 Update |